Novartis COVID-19 Therapy Could Overcome Escape Variant Problem
Protein Therapeutic Enters Pivotal Trial
The DARPin candidate will not gain emergency approval before early 2022, but its likely ability to sustain efficacy regardless of SARS-CoV-2 mutations could be valuable as new variants emerge.
You may also be interested in...
Efforts to find new uses for old drugs in COVID-19 patients are gathering pace.
Actemra finally gains an emergency use authorization, Lilly's antibodies withdrawn again amid Delta variant concerns, plus Latin America’s belief in an anti-parasite drug in COVID-19 could soon be punctured.
Roche presents further analysis on Tecentriq’s potential first-in-class adjuvant use, which could add up to $3bn a year to revenues.